Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5% following the announcement of FDA approval for its eye drop product, marking a significant milestone for the company [1] Group 1: Company Developments - Zhaoke Ophthalmology announced that its partner, Tenpoint Therapeutics, Ltd., received FDA approval for the commercialization of Carbachol and Bromfenac eye drops (2.75%/0.1%) [1] - The eye drop, known as BRIMOCHOL™ PF during clinical trials, will be marketed in the U.S. under the name YUVEZZI™ for the treatment of presbyopia [1] - The FDA approval is seen as a strong catalyst for Zhaoke's commercialization strategy, with the company having established a partnership network across the Asia-Pacific region and the Middle East [1] Group 2: Market Impact - Following the FDA approval announcement, Zhaoke Ophthalmology's stock rose by 5.28%, reaching HKD 3.79, with a trading volume of HKD 6.119 million [1] - The approval is expected to accelerate the market entry of the drug, representing an important global milestone for the company [1]
港股异动 | 兆科眼科-B(06622)再涨超5% 老花眼新药获 FDA 批准上市